Cargando…

Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores

BACKGROUND: The recommendation for chemotherapy in early-stage breast cancer patients has been refined by the 21-gene Recurrence Score. However, uncertainty remains whether patients in the Intermediate Risk category benefit from chemotherapy. METHODS: We analyzed female patients from the National Ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Jonathan, Wu, Xian, Christos, Paul J., Formenti, Silvia, Nagar, Himanshu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903005/ https://www.ncbi.nlm.nih.gov/pubmed/29661221 http://dx.doi.org/10.1186/s13058-018-0957-3

Ejemplares similares

Predictive and Prognostic Value of the 21-Gene Recurrence Score in Hormone Receptor–positive, Node-positive Breast Cancer
por: Brufsky, Adam M.
Publicado: (2014)

The Role of the 21-Gene Recurrence Score(®) Assay in Hormone Receptor-Positive, Node-Positive Breast Cancer: The Canadian Experience
por: Yordanova, Mariya, et al.
Publicado: (2022)

Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer
por: Poorvu, Philip D., et al.
Publicado: (2020)

The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer
por: Thaker, Nikhil G, et al.
Publicado: (2015)

Favorable locoregional control in clinically node-negative hormone-receptor positive breast cancer with low 21-gene recurrence scores: a single-institution study with 10-year follow-up
por: Uras, Cihan, et al.
Publicado: (2022)

Cancer and COVID-19 — potentially deleterious effects of delaying radiotherapy
por: Nagar, Himanshu, et al.
Publicado: (2020)

21-Gene Recurrence Score and Adjuvant Chemotherapy Decision for Breast Cancer Patients with Positive Lymph Nodes
por: Tong, Yiwei, et al.
Publicado: (2019)

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use
por: Eiermann, W., et al.
Publicado: (2013)

Association Between Neutrophil-Lymphocyte Ratio and Oncotype Dx Recurrence Score in Early-Stage Hormonal Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer
por: Alshamsan, Bader, et al.
Publicado: (2021)

The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients
por: Stemmer, Salomon M., et al.
Publicado: (2013)

Comparison of recurrence patterns in cervical cancer patients with positive lymph nodes versus negative
por: Ji, Mei, et al.
Publicado: (2022)

Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients
por: Wu, Jiayi, et al.
Publicado: (2017)

Association between the 21-gene recurrence score and isolated locoregional recurrence in stage I-II, hormone receptor-positive breast cancer
por: Yang, David D., et al.
Publicado: (2020)

The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)
por: Penault-Llorca, Frédérique, et al.
Publicado: (2018)

A Retrospective Study of the Impact of 21-Gene Recurrence Score Assay on Treatment Choice in Node Positive Micrometastatic Breast Cancer
por: Frazier, Thomas G., et al.
Publicado: (2015)

Clinical relevance of the 21-gene Recurrence Score(®) assay in treatment decisions for patients with node-positive breast cancer in the genomic era
por: Mamounas, Eleftherios P., et al.
Publicado: (2018)

BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer
por: Kwon, Mi Jeong, et al.
Publicado: (2018)

Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer
por: Hannouf, Malek B, et al.
Publicado: (2012)

The Clinical Impact of 21-Gene Recurrence Score on Treatment Decisions for Patients with Hormone Receptor-Positive Early Breast Cancer in Korea
por: Lee, Moo Hyun, et al.
Publicado: (2015)

A robust prognostic signature for hormone-positive node-negative breast cancer
por: Griffith, Obi L, et al.
Publicado: (2013)

Prognostic Discrimination Using a 70-Gene Signature among Patients with Estrogen Receptor-Positive Breast Cancer and an Intermediate 21-Gene Recurrence Score
por: Ahn, Sung Gwe, et al.
Publicado: (2013)

Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer
por: Ahn, Sung Gwe, et al.
Publicado: (2018)

Impact of the 21-Gene Recurrence Score Assay on Treatment Decisions and Cost in Patients with Node-Positive Breast Cancer: A Multicenter Study in Quebec
por: Hassan, Saima, et al.
Publicado: (2022)

Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26–30
por: Park, Seho, et al.
Publicado: (2019)

Psychosocial and Quality of Life in Women Receiving the 21-Gene Recurrence Score Assay: The Impact of Decision Style in Women with Intermediate RS
por: Sulayman, Nadiyah, et al.
Publicado: (2012)

Association between TP53 mutation and high 21-gene recurrence score in estrogen receptor-positive/HER2-negative breast cancer
por: Ji, Jung Hwan, et al.
Publicado: (2022)

Association of Body Mass Index With 21-Gene Recurrence Score Among Women With Estrogen Receptor–Positive, ERBB2–Negative Breast Cancer
por: Lee, Janghee, et al.
Publicado: (2022)

Adjuvant chemotherapy for node negative, high Recurrence Score(TM) breast cancer: in defense of de-escalation
por: Lake, Diana, et al.
Publicado: (2019)

Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer
por: Soliman, Hatem, et al.
Publicado: (2020)

Association between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer
por: Chae, Eun Young, et al.
Publicado: (2016)

Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer
por: Kwon, Mi Jeong, et al.
Publicado: (2019)

Association of Survival With Chemoendocrine Therapy in Women With Small, Hormone Receptor–Positive, ERBB2-Positive, Node-Negative Breast Cancer
por: Ma, Sung Jun, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score(®) Test in Node-Negative Early Breast Cancer
por: Berdunov, Vladislav, et al.
Publicado: (2022)

Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate oncotype DX recurrence score results
por: Fried, Georgeta, et al.
Publicado: (2014)

Early and late recurrences in lymph node-negative gastric cancer: a retrospective cohort study
por: Sun, Jian-Wei, et al.
Publicado: (2021)

Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey
por: Ünal, Çağlar, et al.
Publicado: (2023)

Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2− node positive breast cancer—A National Cancer Database study
por: Peethambaram, Prema P., et al.
Publicado: (2017)

Clinical analysis of 21-gene relapse score test in hormone receptor-positive early-stage breast cancer
por: Zhu, Lizhe, et al.
Publicado: (2019)

Clinical analysis of 21-gene relapse score test in hormone receptor-positive early-stage breast cancer
por: Zhu, Lizhe, et al.
Publicado: (2021)

Lymphovascular invasion, race, and the 21-gene recurrence score in early estrogen receptor-positive breast cancer
por: Makower, Della, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f604j5fnftnh85jp8cqua0fuvn